Reactive oxygen species and diabetic nephropathy
Reactive oxygen species and diabetic nephropathy
批准号:
14370319
负责人:
MAKINO Hirofumi
金额:
$5.82万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004
中文摘要
高血糖诱导的线粒体活性氧(ROS)过度产生已成为糖尿病血管并发症的主要因素。哺乳动物线粒体内膜转位酶44 (Tim44)在糖尿病小鼠肾脏中表达上调。Tim44作为mtHsp70 - TIM23复合物的膜锚点,参与线粒体靶向前蛋白进入线粒体基质。该过程依赖于内膜电位(Δψ)和mtHsp70的ATP酶结构域上的ATP水解。将日本血凝病毒(HVJ)包膜载体携带含有Tim44全长cDNA和对照质粒的pcDNA3.1质粒,每周从尾静脉注射到未切除的链脲霉素诱导的糖尿病CD-1小鼠体内。基因传递减轻了注射后8周的蛋白尿和肾肥大,抑制了肾细胞的增殖和凋亡,抑制了超氧化物的产生。在体外实验中,利用人近端小管(HK2)细胞,发现Tim44基因传递逆转了高糖诱导的代谢和细胞异常,如ROS生成增强、ATP含量增加、内膜电位改变、细胞增殖和凋亡增加。用siRNA和Tim44表达载体转染后发现,Tim44可促进超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶等抗氧化酶进入线粒体。因此,Tim44的基因传递似乎有利于线粒体功能的维持,是糖尿病肾病的一种新的治疗方法。
英文摘要
Hyperglycemia-induced overproduction of mitochondrial reactive oxygen species (ROS) has emerged as a major player in diabetic vascular complications. Mammalian translocase of inner mitochondrial membrane 44 (Tim44) was identified by up-regulation in diabetic mouse kidneys. Tim44 functions as a membrane anchor of mtHsp70 to TIM23 complex and involves in the import of mitochondria-targeted preproteins into mitochondrial matrix. The process is dependent on inner membrane potential (Δψ) and ATP hydrolysis on ATPase domain of mtHsp70. Hemagglutination virus of Japan (HVJ)-envelope vector carrying pcDNA3.1 plasmid containing the full length cDNA of Tim44 and control plasmid were weekly injected from tail vein into uninephrectomized streptozotocin-induced diabetic CD-1 mice. The gene delivery alleviated proteinuria and renal hypertrophy at 8 weeks after the injection and inhibited renal cell proliferation and apoptosis, and suppressed superoxide production. In vitro experiments, using human proximal tubular (HK2) cells, revealed that the gene delivery of Tim44 reversed high glucose induced metabolic and cellular abnormalities such as, enhanced ROS production, increased ATP contents, alterations in inner membrane potential, increased cell proliferation and apoptosis. Transfection with siRNA and expressing vector of Tim44 revealed that Tim44 facilitates import of anti-oxidative enzymes such as superoxide dismutase (SOD) and glutathione peroxidase into mitochondria. The gene delivery of Tim44 thus seems to be beneficial for the maintenance of mitochondrial function and is a novel therapeutic approach for diabetic nephropathy.
期刊论文(62)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Okada S et al.: "Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes."Diabetes. 52. 2586-2593 (2003)
Okada S 等人:“细胞间粘附分子 1 缺陷的小鼠在诱导糖尿病后能够抵抗肾损伤。”糖尿病。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
糖尿病性腎症 糖尿病合併症の診かた・考え方
糖尿病肾病 如何诊断和思考糖尿病并发症
DOI:
--
发表时间:
2004
期刊:
影响因子:
--
作者:
[岡田達夫, 和田淳, 槇野博史]
通讯作者:
槇野博史
Elevated serum MCP-4 levels in overweight subjects and its correlation with chronic inflammation.
超重受试者血清 MCP-4 水平升高及其与慢性炎症的相关性。
DOI:
--
发表时间:
2006
期刊:
Obes Res 14(5)
影响因子:
--
作者:
[Hashimoto I, Wada J, Hida A, Baba M, Miyatake N, Eguchi J, Shikata K, Makino H]
通讯作者:
Makino H
Update of extracellular matrix, its receptors, and cell adhesion molecules in mammalian nephroqenesis.
哺乳动物肾病中细胞外基质、其受体和细胞粘附分子的更新。
DOI:
--
发表时间:
2004
期刊:
Am J Physiol Renal Physiol 286(2)
影响因子:
--
作者:
[Kanwar YS, Wada J et al.]
通讯作者:
Wada J et al.
Critical role of SHP-1 in the rHuEPO hyporesponsive anemia in chronic hemodialysis patients.
SHP-1 在慢性血液透析患者 rHuEPO 低反应性贫血中的关键作用。
DOI:
--
发表时间:
2004
期刊:
J Am Soc Nephrol 15(12)
影响因子:
--
作者:
[Akagi S, Ichikawa H et al.]
通讯作者:
Ichikawa H et al.
共 24 条
Nuclear receptors as therapeutic targets for diabeticnephropathy.
-
批准号:21249053
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$29.12万
-
财政年份:2009
-
负责人:MAKINO Hirofumi
-
依托单位:
New therapeutic approach to diabetic nephropathy by modulating mitochondrial function
-
批准号:18390249
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.0万
-
财政年份:2006
-
负责人:MAKINO Hirofumi
-
依托单位:
Molecular mechanism of glomerular hyperfiltration in diabetic nephropathy revealed by gene expression profiling.
-
批准号:11470218
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$10.56万
-
财政年份:1999
-
负责人:MAKINO Hirofumi
-
依托单位:
Application of anti-cell adhesion molecule therapies for renal diseases.
-
批准号:08671287
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1996
-
负责人:MAKINO Hirofumi
-
依托单位:
Role of advanced glycation end-product in the development and progression of diabetic nephropathy.
-
批准号:07671252
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.54万
-
财政年份:1995
-
负责人:MAKINO Hirofumi
-
依托单位:
Molecular biological approach to the abnormalities of extracelluar matrix of the diabetic nephropathy.
-
批准号:04671481
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1992
-
负责人:MAKINO Hirofumi
-
依托单位:
Glomerular proteoglycans in diabetic nephropathy
-
批准号:01570644
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1989
-
负责人:MAKINO Hirofumi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
SIRT3/FoxO3a/ROS通路介导的铁死亡在脓毒症肌肉萎缩中的作用及机制研究
-
批准号:2026JJ30096
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:谢鹏
-
依托单位:
基于巨噬细胞MPO缺失的线粒体ROS/KLF4通路对动脉粥样硬化斑块不稳定性的机制研究
-
批准号:2026JJ82110
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黄江伟
-
依托单位:
基于ROS/TXNIP/NLRP3信号通路介导的细胞焦亡途径探讨慢阻肺舒颗粒对慢性阻塞性肺疾病急性加重期(AECOPD)痰热壅肺证大鼠模型的干预机制
-
批准号:2026JJ80947
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李柯
-
依托单位:
双功能COFs基S型异质结的精准构建及其光催化产H2O2驱动ROS级联杀菌的机制研究
-
批准号:2026JJ80004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张淑敏
-
依托单位:
IDO1源性线粒体ROS介导血水草提取物原阿片碱抗血小板聚集
-
批准号:2026JJ80210
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:轩贵平
-
依托单位:
ROS响应性泡沫细胞靶向调节脂质稳态治疗动脉粥样硬化
-
批准号:2026JJ81260
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:邓丹
-
依托单位:
抗阻训练激活ROS/PRDX3/FUNDC1信号轴调控线粒体自噬延缓肌少症的机制研究
-
批准号:JCZRQNB202600588
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于pH/ROS智能响应的大黄酸仿生水凝胶构建及其调控OA炎症微环境促进软骨再生的作用机制
-
批准号:2026JJ70138
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘之晨
-
依托单位:
大黄酸通过PPARG/SHMT1/NOX1轴抑制ROS依赖性血管平滑肌细胞焦亡改善慢性肾衰竭血管钙化的机制研究
-
批准号:2026JJ82590
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:熊丹
-
依托单位:
姜黄素脂质体协同CDK4/6抑制剂通过ROS/DNA损伤通路阻遏乳腺癌转移的机制研究
-
批准号:JCZRLH202600107
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: